Nutriband Chairman to Present at NobleCon21 Investor Conference

Nutriband Inc. (NASDAQ: NTRB) announced that Chairman and Co-Founder Serguei Melnik will present at NobleCon21, Noble Capital Markets' annual emerging growth equity conference. The presentation is scheduled for December 3 at 9:30 a.m. Eastern Time at Florida Atlantic University's Executive Education Complex in Boca Raton, Florida.

Investors and conference guests can attend at a discounted rate using the code NTRBNOBLECON. For those unable to attend in person, a high-definition webcast will be available the following day at nobleconference.com and Channelchek.com, where it will remain archived for 90 days.

Nutriband is primarily engaged in developing a portfolio of transdermal pharmaceutical products. The company's lead product under development is an abuse-deterrent fentanyl patch incorporating its proprietary AVERSA™ abuse-deterrent technology. This technology represents a significant advancement in transdermal drug delivery systems, designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The AVERSA™ technology platform can be incorporated into any transdermal patch, offering broad applications across the pharmaceutical industry. This flexibility positions Nutriband as a potential partner for other pharmaceutical companies seeking to enhance the safety profile of their transdermal products. The company maintains its corporate website at www.nutriband.com.

Participation in NobleCon21 provides Nutriband with a platform to showcase its technological innovations to a targeted audience of investors and industry professionals. Emerging growth conferences like NobleCon21 serve as critical venues for companies to demonstrate their progress, business models, and growth potential to the investment community.

The timing of this presentation comes as the pharmaceutical industry faces increasing pressure to address the opioid crisis and improve drug safety. Nutriband's focus on abuse-deterrent technologies aligns with regulatory priorities and public health initiatives aimed at reducing prescription drug abuse. The company's approach to transdermal drug delivery could have significant implications for patient safety and drug compliance across multiple therapeutic areas.

For investors and industry observers, Melnik's presentation offers an opportunity to gain deeper insights into Nutriband's development pipeline, commercialization strategy, and the potential market impact of its AVERSA™ technology. The archived webcast availability ensures broader accessibility for interested parties who cannot attend the live event, supporting transparent communication with the investment community.